Spots Global Cancer Trial Database for Early Cancer Detection Test - Lung Cancer China
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Early Cancer Detection Test - Lung Cancer China
Official Title: Clinic Validation of Autoantibody Panel for Lung Cancer Diagnosis in Chinese Population
Study ID: NCT04216511
Conditions
Interventions
Study Description
Brief Summary: Lung cancer is the most common cancer in China from both incidence and mortality rate point of view, with significantly lower 5-year survival rate than average. Early detection is the recognized solution. LDCT is more and more popular accepted as an effective screening methodology but leads to numerous indeterminate pulmonary nodules for physicians to distinguish too. The value of autoantibody test in risk assessing of IPNs as well as early detection of lung cancer in high risk population has been demonstrated in clinical practice and trial but mainly in Caucasian. Purpose of this study is to understand the sensitivity, specificity and accuracy of candidate autoantibodies, and consequently explore the autoantibody combination with best clinical performance in Chinese population.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Zhongshan Hospital of Fudan University, Shanghai, Shanghai, China
Shanghai Chest Hospital, Shanghai, , China
Henan Province People's Hospital, Zhengzhou, , China
Contact Details
Name: Chunxue Bai, MD
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
